VALN
Valneva SE ADRNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$562.30M
P/E Ratio
—
EPS
$-1.86
Beta
1.33
52W High
$12.25
52W Low
$5.06
50-Day MA
$6.45
200-Day MA
$8.88
Dividend Yield
—
Profit Margin
-88.30%
Forward P/E
666.67
PEG Ratio
—
About Valneva SE ADR
Valneva SE, a company specialized in vaccines, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. The company is headquartered in Saint-Herblain, France.
Fundamentals
| Revenue (TTM) | $156.33M |
| Gross Profit (TTM) | $-39.25M |
| EBITDA | $-81.88M |
| Operating Margin | -76.70% |
| Return on Equity | -109.60% |
| Return on Assets | -14.50% |
| Revenue/Share (TTM) | $1.79 |
| Book Value | $1.00 |
| Price-to-Book | 6.33 |
| Price-to-Sales (TTM) | 3.60 |
| EV/Revenue | 3.669 |
| EV/EBITDA | 26.94 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -37.20% |
| Shares Outstanding | $94.82M |
| Float | $147.38M |
| % Insiders | 0.00% |
| % Institutions | 4.13% |
Analyst Ratings
Consensus ($12.20 target)
3
Buy1
SellMore HEALTHCARE Stocks
Data last updated: 5/25/2026